Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-22-031997
Filing Date
2022-09-01
Accepted
2022-09-01 16:45:07
Documents
14
Period of Report
2022-07-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A brhc10041542_8ka.htm   iXBRL 8-K/A 35765
2 EXHIBIT 10.1 brhc10041542_ex10-1.htm EX-10.1 68664
6 logo01.jpg GRAPHIC 6101
  Complete submission text file 0001140361-22-031997.txt   267958

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20220721.xsd EX-101.SCH 3871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220721_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220721_pre.xml EX-101.PRE 16049
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10041542_8ka_htm.xml XML 4247
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-11460 | Film No.: 221221451
SIC: 2834 Pharmaceutical Preparations